CORRELATIVE ANALYSIS OF BLOOD AND BIOPSY SAMPLES FROM A CLINICAL TRIAL OF HSP90 INHIBITION IN COMBINATION WITH PEMBROLIZUMAB REVEALS INCREASED INTRATUMORAL MYELOID CELL ACCUMULATION AFTER TREATMENT

1Cameron Herting*, 2Yuchen Zhang, 1Deon Doxie, 1Michael Ware, 1Olatunji Aleshe, 1Christina Wu, 1Mehmet Akca, 1Mohammad Zaidi, 1Amanda Ruggieri, 1Madhav Dhodapkar, 1Kavita Dhodapkar, 1Juan Sarmiento, 1Rafi Ahmed, 1Shishir Maithel, 1Bassel El-Rayes, 2Gregory Lesinski. 1Emory University, Decatur, GA, USA; 2Xi’an Jiaotong University, Shaanxi, China

Background Pancreatic ductal adenocarcinoma (PDAC) has yet to widely benefit from T cell-targeted immunotherapy and displays universally poor prognosis. Thus, enhancing the activity of immunotherapy is a high priority. Our laboratory recently reported that heat shock protein-90 (Hsp90) inhibition enhances the efficacy of PD-1 blockade in murine models of PDAC (Zhang Y. et al., Mol Cancer Ther, 2020). Hsp90 inhibitors can limit activation of cancer associated fibroblasts (CAF) and promote infiltration of T cells when combined with PD-1 blockade in preclinical systems.

Methods Based on these data, we are conducting a Phase Ib/II clinical trial to evaluate the combination of XL888 (Hsp90 inhibitor) and pembrolizumab in patients with metastatic pancreatic cancer. We hypothesize that this combination will be safe and elicit pronounced microenvironmental changes, leading to enhanced efficacy of checkpoint blockade in a tumor type that is otherwise refractory to this approach. During the phase II portion patients were randomized to receive a three week lead in with either pembrolizumab or pembrolizumab and XL888. Paired biopsies and blood samples were obtained at baseline and at week two on treatment and CyTOF was used to assess changes in circulating and tumor infiltrating immune populations. Further, CyTOF profiling of circulating immune cells was performed to assess impacts of XL888 on over thirty phenotypically defined immune populations (figure 1).

Results As of June 2021, paired liver biopsy specimens from sites of metastasis have been successfully obtained from a total of 8 patients and paired peripheral blood mononuclear cell samples have been analyzed in 24 patients. Our CyTOF analysis illustrated a surprising increase in myeloid cell populations within the tumor following treatment. Analysis of circulating immune cells illustrated a decrease in natural killer cells and Th17 populations following treatment while naïve B cells were increased. These data will be validated by immunohistochemical analysis of FFPE biopsy specimens obtained in parallel at the time of CyTOF analysis. The impact of XL888 on systemic cytokines and chemokines (n=48 total) in the peripheral blood from patients enrolled in the clinical trial is therefore being assessed as a potential mechanism to explain this observation.

Conclusions Clinical data from this trial indicates that this combination is safe in patients. As clinical data matures, changes in soluble and cellular biomarkers will be correlated with response to elucidate mechanisms of response or resistance to this combination therapy.

Trial Registration This clinical trial is underway and registered with the ID NCT03095781

Ethics Approval The study was approved by Emory University’s Ethics Board, approval IRB00087397.

Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

http://dx.doi.org/10.1136/jitc-2021-SITC2021.403